Search
Results: 20
Modelling norovirus transmission and vaccination.
deterministic Markov model mathematical model Norovirus ODEs vaccine Adolescent Adult Aged Caliciviridae Infections Child Child Preschool Cost-Benefit Analysis Female Gastroenteritis Germany Humans Infant Infant Newborn Male Markov Chains Middle Aged Models Theoretical Monte Carlo Method Norovirus Vaccination Viral Vaccines Young Adult
Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.
The increasing frequency of monkeypox virus infections, new outbreaks of other zoonotic orthopoxviruses and concern about the re-emergence of smallpox have prompted research into developing antiviral drugs and better vaccines...
Genetic Engineering Immune Evasion immunological memory orthopoxviruses smallpox vaccine vaccinia virus Animals Communicable Diseases Emerging Cytokines Genetic Engineering Humans Immunity Immunogenicity Vaccine Immunologic Memory immunomodulation Inflammation Mediators smallpox smallpox vaccine vaccinia virus Viral Vaccines Zoonoses
The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination
Grigorios D Amoutzias, Marios Nikolaidis, Eleni Tryfonopoulou, Katerina Chlichlia, Panayotis Markoulatos, Stephen G Oliver
Feb 22, 2022
Coronaviruses (CoVs) constitute a large and diverse subfamily of positive-sense single-stranded RNA viruses. They are found in many mammals and birds and have great importance for the health of humans and farm animals. The...
Temperature Sensitivity
Sarah Keep, Phoebe Stevenson-Leggett, Angela Steyn, Michael S Oade, Isobel Webb, Jamie Stuart, Lonneke Vervelde, Paul Britton, Helena J Maier, Erica Bickerton
Jul 17, 2020
The Gammacoronavirus infectious bronchitis virus (IBV) is a highly contagious economically important respiratory pathogen of domestic fowl. Reverse genetics allows for the molecular study of pathogenic determinants to enable...
SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa.
Adam Abdullahi, David Oladele, Michael Owusu, Steven A Kemp, James Ayorinde, Abideen Salako, Douglas Fink, Fehintola Ige, Isabella ATM Ferreira, Bo Meng, Augustina Angelina Sylverken, Chika Onwuamah, Kwame Ofori Boadu, Kazeem Osuolale, James Opoku Frimpong, Rufai Abubakar, Azuka Okuruawe, Haruna Wisso Abdullahi, Gideon Liboro, Lawrence Duah Agyemang, Nana Kwame Ayisi-Boateng, Oluwatosin Odubela, Gregory Ohihoin, Oliver Ezechi, Japhet Senyo Kamasah, Emmanuel Ameyaw, Joshua Arthur, Derrick Boakye Kyei, Dorcas Ohui Owusu, Olagoke Usman, Sunday Mogaji, Adedamola Dada, George Agyei, Soraya Ebrahimi, Lourdes Ceron Gutierrez, Sani H Aliyu, Rainer Doffinger, Rosemary Audu, Richard Adegbola, Petra Mlcochova, Richard Odame Phillips, Babatunde Lawal Solako, Ravindra K Gupta
Nov 17, 2022
Real-world data on vaccine-elicited neutralising antibody responses for two-dose AZD1222 in African populations are limited. We assessed baseline SARS-CoV-2 seroprevalence and levels of protective neutralizing antibodies prior...
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Simeng Lin, Nicholas A Kennedy, Aamir Saifuddin, Diana Muñoz Sandoval, Catherine J Reynolds, Rocio Castro Seoane, Sherine H Kottoor, Franziska P Pieper, Kai-Min Lin, David K Butler, Neil Chanchlani, Rachel Nice, Desmond Chee, Claire Bewshea, Malik Janjua, Timothy J McDonald, Shaji Sebastian, James L Alexander, Laura Constable, James C Lee, Charles D Murray, Ailsa L Hart, Peter M Irving, Gareth-Rhys Jones, Klaartje B Kok, Christopher A Lamb, Charlie W Lees, Daniel M Altmann, Rosemary J Boyton, James R Goodhand, Nick Powell, Tariq Ahmad, CLARITY IBD study
Apr 19, 2022
Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune...
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK
Xinxue Liu, Alasdair PS Munro, Shuo Feng, Leila Janani, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Wanwisa Dejnirattisai, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L Goodman, Christopher A Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A van der Klaauw, Jonathan Kwok, Vincenzo Libri, Martin J Llewelyn, Alastair C McGregor, Angela M Minassian, Patrick Moore, Mehmood Mughal, Yama F Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Teona Serafimova, Dinesh Saralaya, Gavin R Screaton, Sunil Sharma, Ray Sheridan, Ann Sturdy, Piyada Supasa, Emma C Thomson, Shirley Todd, Chris Twelves, Robert C Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S Nguyen-Van-Tam, Victoria Cornelius, Matthew D Snape, Saul N Faust, COV-BOOST study group
May 13, 2022
OBJECTIVES: To evaluate the persistence of immunogenicity three months after third dose boosters. METHODS: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster...
COVID-19 vaccine Fractional dose Heterologous boost Homologous boost Immunogenicity Persistence Third dose Ad26COVS1 Adult Aged Aged 80 and over Antibodies Viral BNT162 Vaccine covid-19 COVID-19 Vaccines ChAdOx1 nCoV-19 Humans Immunogenicity Vaccine Immunoglobulin G Middle Aged SARS-CoV-2 United Kingdom Viral Vaccines mRNA Vaccines
SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency
Adrian M Shields, Sian E Faustini, Harriet J Hill, Saly Al-Taei, Chloe Tanner, Fiona Ashford, Sarita Workman, Fernando Moreira, Nisha Verma, Hollie Wagg, Gail Heritage, Naomi Campton, Zania Stamataki, Paul Klenerman, James ED Thaventhiran, Sarah Goddard, Sarah Johnston, Aarnoud Huissoon, Claire Bethune, Suzanne Elcombe, David M Lowe, Smita Y Patel, Sinisa Savic, Siobhan O Burns, Alex G Richter, COV-AD consortium
Aug 25, 2022
BACKGROUND: Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood....
Immunoinformatics design of multivalent epitope vaccine against monkeypox virus and its variants using membrane-bound, enveloped, and extracellular proteins as targets.
Muhammad Waqas, Shahkaar Aziz, Pietro Liò, Yumna Khan, Amjad Ali, Aqib Iqbal, Faizullah Khan, Fahad Nasser Almajhdi
Feb 09, 2023
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
Juan García-Arriaza, Beatriz Perdiguero, Jonathan Heeney, Michael Seaman, David C Montefiori, Celia Labranche, Nicole L Yates, Xiaoying Shen, Georgia D Tomaras, Guido Ferrari, Kathryn E Foulds, Adrian McDermott, Shing-Fen Kao, Mario Roederer, Natalie Hawkins, Steve Self, Jiansheng Yao, Patrick Farrell, Sanjay Phogat, Jim Tartaglia, Susan W Barnett, Brian Burke, Anthony Cristillo, Deborah Weiss, Carter Lee, Karen Kibler, Bert Jacobs, Benedikt Asbach, Ralf Wagner, Song Ding, Giuseppe Pantaleo, Mariano Esteban
Jun 19, 2015
Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak.
Peter Willeit, Janine Kimpel, Hannes Winner, Teresa Harthaller, Helena Schäfer, David Bante, Barbara Falkensammer, Annika Rössler, Lydia Riepler, Cornelia Ower, Magdalena Sacher, Dorothee von Laer, Wegene Borena
Sep 23, 2022
SARS-COV-2 vaccine responses in renal patient populations.
Rona M Smith, Daniel J Cooper, Rainer Doffinger, Hannah Stacey, Abdulrahman Al-Mohammad, Ian Goodfellow, Stephen Baker, Sara Lear, Myra Hosmilo, Nicholas Pritchard, Nicholas Torpey, David Jayne, Vivien Yiu, Anil Chalisey, Jacinta Lee, Enric Vilnar, Chee Kay Cheung, Rachel B Jones
Jun 07, 2022
BACKGROUND: Dialysis patients and immunosuppressed renal patients are at increased risk of COVID-19 and were excluded from vaccine trials. We conducted a prospective multicentre study to assess SARS-CoV-2 vaccine antibody...
Economists must collaborate courageously.
Diane Coyle
May 26, 2020
Economists, like researchers in many natural science disciplines, are responding to the urgency of the pandemic. The immediate priorities are understanding the consequences of the crisis for public finances, the collapse of...
Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).
Rachael Chiam, Emma Sharp, Sushila Maan, Shujing Rao, Peter Mertens, Barbara Blacklaws, Nick Davis-Poynter, James Wood, Javier Castillo-Olivares
Mar 13, 2020
BACKGROUND: African horse sickness virus (AHSV) causes a non-contagious, infectious disease in equids, with mortality rates that can exceed 90% in susceptible horse populations. AHSV vaccines play a crucial role in the control...
Clinical, Virological and Immunological Responses after Experimental Infection with African Horse Sickness Virus Serotype 9 in Immunologically Naïve and Vaccinated Horses.
Manuel Durán-Ferrer, Rubén Villalba, Paloma Fernández-Pacheco, Cristina Tena-Tomás, Miguel-Ángel Jiménez-Clavero, José-Antonio Bouzada, María-José Ruano, Jovita Fernández-Pinero, Marisa Arias, Javier Castillo-Olivares, Montserrat Agüero
Sep 02, 2022
This study described the clinical, virological, and serological responses of immunologically naïve and vaccinated horses to African horse sickness virus (AHSV) serotype 9. Naïve horses developed a clinical picture resembling the...
Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators.
IRF3 inhibitor Immunogenicity NF-κB inhibitor Vaccine efficacy vaccinia virus Animals Antibodies Neutralizing Antibodies Viral CD8-Positive T-Lymphocytes Female Gene Deletion Genes Viral Immunogenicity Vaccine Immunologic Factors Immunologic Memory Mice Mice Inbred BALB C Mice Inbred C57BL Vaccine Potency vaccines Attenuated Vaccinia vaccinia virus Viral Proteins Viral Vaccines
From COVID-19 research to vaccine application
It is often said that it takes 17 years to move medical research from bench to bedside. In a coronavirus disease (COVID-19) world, such time-lags feel intolerable. In these extraordinary circumstances could years be made into...
covid-19 Coronavirus disease matrix pandemic Research translation SARS-CoV-2 Time-lags Timescales Trials vaccine World Health Organization Betacoronavirus Biomedical Research covid-19 COVID-19 Vaccines Coronavirus Infections Drug Approval Drug Discovery Humans Pandemics Pneumonia Viral Risk Assessment SARS-CoV-2 Time Factors Translational Research Biomedical Viral Vaccines
Enhancement of CD8(+) T-cell memory by removal of a vaccinia virus nuclear factor-κB inhibitor.
Hongwei Ren, Brian J Ferguson, Carlos Maluquer de Motes, Rebecca P Sumner, Laura ER Harman, Geoffrey L Smith
Mar 20, 2015
Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation
Adrian M Shields, Sian E Faustini, Harriet J Hill, Saly Al-Taei, Chloe Tanner, Fiona Ashford, Sarita Workman, Fernando Moreira, Nisha Verma, Hollie Wagg, Gail Heritage, Naomi Campton, Zania Stamataki, Mark T Drayson, Paul Klenerman, James ED Thaventhiran, Shuayb Elkhalifa, Sarah Goddard, Sarah Johnston, Aarnoud Huissoon, Claire Bethune, Suzanne Elcombe, David M Lowe, Smita Y Patel, Sinisa Savic, Alex G Richter, Siobhan O Burns, COV-AD consortium
Jun 16, 2022
BACKGROUND: Patients with primary and secondary antibody deficiency are vulnerable to COVID-19 and demonstrate diminished responses following two-dose SARS-CoV-2 vaccine schedules. Third primary vaccinations have been deployed...